Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tifcemalimab and Toripalimab with Chemotherapy in Stage III NSCLC
NCT05891080Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of tifcemalimab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Pathologic Complete Response Rate at 30 months. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
tifcemalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05891080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05891080.